{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053940","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2026-08-06T12:49:15+00:00","discovered_at":"2026-08-06T12:50:01.049529+00:00","generated_at":"2026-08-06T12:50:07.578425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track","bullets":["Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.","Completed enrollment in MAD portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data expected Q4 2026.","Proposed merger with Clywedog expected to close H2 2026; combined company to trade as CLYD.","Received Nasdaq extension to Dec 28, 2026 to regain bid price compliance; ADS transferred to Nasdaq Capital Market.","R&D expenses $3.9M (up from $3.6M Q1); G&A expenses $7.1M (up from $2.5M) due to FX losses and professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053940","json":"https://secwatch.observer/filing/0001628280-26-053940.json","markdown":"https://secwatch.observer/filing/0001628280-26-053940.md","text":"https://secwatch.observer/filing/0001628280-26-053940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/0001628280-26-053940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:50:07.578425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}